The US Food and Drug Administration has granted breakthrough therapy designation to an EGFR tyrosine kinase inhibitor for the first-line treatment of EGFR-positive non-small cell lung cancer. READ MORE

Conferences

The NCCN has announced some new changes to its guidelines for non-small cell lung cancer that reflect more recent data.

READ MORE

News

First-line treatment with alectinib prolonged progression-free survival with less toxicity compared with crizotinib in patients with ALK-positive non-small-cell lung cancer.

READ MORE

The US FDA has granted accelerated approval to a treatment for patients with a type of lung cancer who have progressed on initial therapy.

READ MORE

Research in Review

Patients with advanced non-small cell lung cancer who receive previous radiotherapy are more likely to benefit from immunotherapy than those patients without previous radiotherapy.

READ MORE

Adjuvant treatment with the targeted therapy gefitinib significantly improved disease-free survival over standard of care after surgery for patients with non–small cell lung cancer, according to research that will be presented at the 2017 ASCO Annual Meeting.

READ MORE

Selecting patients with cyclooxygenase-2 expression by immunohistochemistry fails to improve survival outcomes in non-small cell lung cancer.

READ MORE

Patients with ALK-rearranged non-small cell lung cancer who are treated with crizotinib may experience increased progression-free survival with a decrease in a type of circulating tumor cells.

READ MORE